Evidence map›Paper›PMID 25037223›Full record

ArticleThe Journal of biological chemistry2014

The intestinal epithelial cell differentiation marker intestinal alkaline phosphatase (ALPi) is selectively induced by histone deacetylase inhibitors (HDACi) in colon cancer cells in a Kruppel-like factor 5 (KLF5)-dependent manner.

Joongho Shin, Azadeh Carr, Georgia A Corner, Lars Tögel, Mercedes Dávalos-Salas, Mercedes Dávaos-Salas, Hoanh Tran, Anderly C Chueh, Sheren Al-Obaidi, Fiona Chionh and 11 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. World journal of experimental medicine · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 4 countries.

Joongho ShinFrom the Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10461.
Azadeh CarrFrom the Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10461.
Georgia A Cornerthe Ludwig Institute for Cancer Research, Austin Health, Melbourne 3084, Australia.
Lars Tögelthe Ludwig Institute for Cancer Research, Austin Health, Melbourne 3084, Australia.
Mercedes Dávalos-Salasthe Ludwig Institute for Cancer Research, Austin Health, Melbourne 3084, Australia.
Mercedes Dávaos-Salasthe Ludwig Institute for Cancer Research, Austin Health, Melbourne 3084, Australia.
Hoanh Tranthe Ludwig Institute for Cancer Research, Austin Health, Melbourne 3084, Australia.
Anderly C Chuehthe Ludwig Institute for Cancer Research, Austin Health, Melbourne 3084, Australia.
Sheren Al-Obaidithe Ludwig Institute for Cancer Research, Austin Health, Melbourne 3084, Australia.
Fiona Chionhthe Ludwig Institute for Cancer Research, Austin Health, Melbourne 3084, Australia.
Naseem AhmedFrom the Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10461.
Daniel D Buchananthe Queensland Institute of Medical Research, 300 Herston Road, Herston, Queensland 4006, Australia.
Joanne P Youngthe Queensland Institute of Medical Research, 300 Herston Road, Herston, Queensland 4006, Australia.
Madhu S Malothe Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02115.
Richard A Hodinthe Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02115.
Diego Arangothe Group of Molecular Oncology, Centro en Investigación en Bioquímica y Biología Molecular-Nanomedicine, Vall d'Hebron University Hospital, Research Institute, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron, 119-129, 08035 Barcelona, Spain and El Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, Spain.
Oliver M Sieberthe Walter and Eliza Hall Institute, Melbourne 3052, Australia.
Leonard H AugenlichtFrom the Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10461.
Amardeep S DhillonPeter MacCallum Cancer Center, Melbourne 3002, Australia, and.
Thomas K Weberthe Veterans Affairs New York Harbor Health Care System, Brooklyn, New York 11209.
John M MariadasonFrom the Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10461, the Ludwig Institute for Cancer Research, Austin Health, Melbourne 3084, Australia, john.mariadason@ludwig.edu.au.
Ludwig Cancer Research · BEAlbert Einstein College of Medicine · USMontefiore Medical Center · USQIMR Berghofer Medical Research Institute · AUHarvard University · USMassachusetts General Hospital · USPeter MacCallum Cancer Centre · AUUniversitat Autònoma de Barcelona · ESVA NY Harbor Healthcare System · USWalter and Eliza Hall Institute of Medical Research · AU

Funding

Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3M
NIDDK NIH HHS P30 DK043351
6 · The paper itself

Abstract

The histone deacetylase inhibitor (HDACi) sodium butyrate promotes differentiation of colon cancer cells as evidenced by induced expression and enzyme activity of the differentiation marker intestinal alkaline phosphatase (ALPi). Screening of a panel of 33 colon cancer cell lines identified cell lines sensitive (42%) and resistant (58%) to butyrate induction of ALP activity. This differential sensitivity was similarly evident following treatment with the structurally distinct HDACi, MS-275. Resistant cell lines were significantly enriched for those harboring the CpG island methylator phenotype (p = 0.036, Chi square test), and resistant cell lines harbored methylation of the ALPi promoter, particularly of a CpG site within a critical KLF/Sp regulatory element required for butyrate induction of ALPi promoter activity. However, butyrate induction of an exogenous ALPi promoter-reporter paralleled up-regulation of endogenous ALPi expression across the cell lines, suggesting the presence or absence of a key transcriptional regulator is the major determinant of ALPi induction. Through microarray profiling of sensitive and resistant cell lines, we identified KLF5 to be both basally more highly expressed as well as preferentially induced by butyrate in sensitive cell lines. KLF5 overexpression induced ALPi promoter-reporter activity in resistant cell lines, KLF5 knockdown attenuated butyrate induction of ALPi expression in sensitive lines, and butyrate selectively enhanced KLF5 binding to the ALPi promoter in sensitive cells. These findings demonstrate that butyrate induction of the cell differentiation marker ALPi is mediated through KLF5 and identifies subsets of colon cancer cell lines responsive and refractory to this effect.

Indexed as

Alkaline PhosphataseBenzamidesBinding SitesBlotting, WesternButyric AcidCell DifferentiationCell Line, TumorColonic NeoplasmsCpG IslandsDNA MethylationDrug Resistance, NeoplasmEpithelial CellsGene Expression ProfilingHCT116 CellsHistone Deacetylase InhibitorsHT29 CellsAlkaline PhosphataseBenzamidesButyric AcidentinostatHistone Deacetylase InhibitorsKLF5 protein, humanKruppel-Like Transcription FactorsPyridinesCIMPColon CancerDifferentiationDNA MethylationHDACHistone Deacetylase Inhibitor (HDAC Inhibitor) (HDI)Kruppel-like Factor (KLF)

Identifiers

PMID25037223
PMCPMC4155692
OpenAlexW1990579775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.